Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > pSivida cancer cure ready for human testing

April 6th, 2004

pSivida cancer cure ready for human testing

Abstract:
pSivida Limited (PSD) today announced that its Singaporean subsidiary, pSiOncology Pte Ltd has successfully completed a final pre-clinical study for its lead BioSiliconTM product, BrachySilTM. This important and final pre-clinical milestone now paves the way for a ‘first in man’ evaluation of both BioSilicon and BrachySil, they announced. BrachySil is the Company’s lead product and is targeted to the substantial brachytherapy market, which is currently worth $600 million and expected to exceed US$1 billion by 2005.

Source:
egoli

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015

Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015

Nanoliposomes Help Efforts to Cure Bacterial Infections January 27th, 2015

Stomach acid-powered micromotors get their first test in a living animal January 27th, 2015

Announcements

Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015

Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015

'Bulletproof' battery: Kevlar membrane for safer, thinner lithium rechargeables January 28th, 2015

Spider electro-combs its sticky nano-filaments January 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE